Evidence of androgen action in endometrial and ovarian cancers
The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Abstract
Endometrial cancer (EC) and ovarian cancer are common gynaecological malignancies. The impact of androgen action in these cancers is poorly understood; however, there is emerging evidence to suggest that targeting androgen signalling may be of therapeutic benefit. Epidemiological evidence suggests that there is an increased risk of EC associated with exposure to elevated levels of androgens, and genetic variants in genes related to both androgen biosynthesis and action are associated with an increased risk of both EC and ovarian cancer. Androgen receptors (ARs) may be a potential therapeutic target in EC due to reported anti-proliferative activities of androgens. By contrast, androgens may promote growth of some ovarian cancers and anti-androgen therapy has been proposed. Introduction of new therapies targeting ARs expressed in EC or ovarian cancer will require a much greater understanding of the impacts of cell context-specific AR-dependent signalling and how ARs can crosstalk with other steroid receptors during progression of disease. This review considers the evidence that androgens may be important in the aetiology of EC and ovarian cancer with discussion of evidence for androgen action in normal and malignant endometrial and ovarian tissue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comparison between the patterns of expression of receptor proteins in normal endometrium with samples of endometrial cancer and endometriosis lesions has revealed evidence of aberrant expression of both AR and ERs, which may result in novel disease-specific targets for the action of steroids generated by intracrine activation/metabolism discussed below.”
From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [26]
In the citing paper
“We and others have shown that AR are widely expressed in EC and also in EC cell lines such as Ishikawa, which have been extensively studied (reviewed in [26]).”
From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [26]
In the citing paper
“We and others have shown that AR are widely expressed in EC and also in EC cell lines such as Ishikawa, which have been extensively studied (reviewed in [26]).”
From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [26]
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293 · cited 2×
“In the UK, it is the fifth most common female cancer (http://www.cancerresearchuk.org/) consistent with higher incidence in high-resource countries (Ferlay et al. 2010).”
BackgroundIntegrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
Spada, A. R. L., Wilson, E. M., Lubahn, D. B., Harding, A. E., & Fischbeck, K. H. (1991) · Nature · doi:10.1038/352077a0 · Cited by 2,784 · cited 1×
“One of the most studied polymorphisms of the AR NTD is the CAG-repeat sequence encoding poly-glutamine repeats (Spada et al. 1991).”
BackgroundTHE JOURNAL OF REPRODUCTIVE MEDICINE: PATIENT ANXIETY DURING GYNECOLOGIC EXAMINATIONS
Reddy, D. M., & Wasserman, S. A. (1999) · American Journal of Nursing · doi:10.1097/00000446-199901000-00024 · Cited by 2,483
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,791
Reeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. (2007) · BMJ · doi:10.1136/bmj.39367.495995.ae · Cited by 1,507
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Prat, J. (2014) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2013.10.001 · Cited by 1,364 · cited 1×
“According to a recent report from FIGO, ovarian cancer is the seventh most common cancer in women worldwide (Prat 2013).”
BackgroundChamberlain, N. L., Driver, E. D., & Miesfeld, R. L. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.15.3181 · Cited by 1,156 · cited 1×
“The length of the CAG-repeat region correlates inversely with AR transactivation capability (Chamberlain et al. 1994).”
BackgroundMolecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Kurman, R. J., & Shih, I.-M. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.03.003 · Cited by 1,073
Research works printed but not linked: 9
- 2008, NUCLEAR RECEPTOR SIGNALING, 6, 008e
- Horie, 1992, Human Reproduction, 7, 184, 10.1093/humrep/ · doi:10.1093/humrep/
- Li, 2003, Clinical Cancer Research, 9, 3667
- 2011, JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 16, 999
- 1996, HUMAN CELL, 9, 109
- 2013, INTERNATIONAL JOURNAL OF GYNAECOLOGY AND OBSTETRICS, 124, 1
- Rabban, 2005, The Journal of reproductive medicine, 50, 467
- Syed, 2001, Cancer Research, 61, 6768
- 2013, EMBO MOLECULAR MEDICINE, 5, 983
Cited by
Wang, Y.-X., Arvizu, M., Rich-Edwards, J. W., Stuart, J. J., Manson, J. E., Missmer, S. A., Pan, A., & Chavarro, J. E. (2020) · BMJ · doi:10.1136/bmj.m3464 · Cited by 178
Wiwatpanit, T., Murphy, A. R., Lu, Z., Urbanek, M., Burdette, J. E., Woodruff, T. K., & Kim, J. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz100 · Cited by 135
Androgens and endometrium: new insights and new targets
Simitsidellis, I., Saunders, P. T. K., & Gibson, D. A. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.09.022 · Cited by 107
Self-citationEpidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences
Felix, A. S., Yang, H., Bell, D. W., & Sherman, M. E. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_1 · Cited by 107
SiRNA and epigenetic aberrations in ovarian cancer
Mirzaei, H., Yazdi, F., Salehi, R., & Mirzaei, H. R. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.153661 · Cited by 106
The role of androgens in women's health and wellbeing
Bianchi, V. E., Bresciani, E., Meanti, R., Rizzi, L., Omeljaniuk, R. J., & Torsello, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105758 · Cited by 97
Watts, E. L., Perez‐Cornago, A., Knüppel, A., Tsilidis, K. K., Key, T. J., & Travis, R. C. (2021) · International Journal of Cancer · doi:10.1002/ijc.33555 · Cited by 88
“There is also some evidence that testosterone might affect endometrial and breast cancer risk more directly via androgen receptor signaling.(50,51)”
BackgroundKamal, A. M., Bulmer, J. N., DeCruze, S. B., Stringfellow, H. F., Martin-Hirsch, P., & Hapangama, D. K. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.16 · Cited by 84
Whitaker, L. H. R., Murray, A. A., Matthews, R., Shaw, G., Williams, A. R. W., Saunders, P. T. K., & Critchley, H. O. D. (2017) · Human Reproduction · doi:10.1093/humrep/dew359 · Cited by 77
“The impact of androgens on development of endometrial malignancy is complex (Gibson et al., 2014) and further studies on the relationship between UPA and AR are merited.”
Self-citationAndrogens, oestrogens and endometrium: a fine balance between perfection and pathology
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0106 · Cited by 76
Self-citationAndrogen receptor as potential therapeutic target in metastatic endometrial cancer
Tangen, I. L., Onyango, T. B., Kopperud, R., Berg, A., Halle, M. K., Øyan, A. M., Werner, H. M. J., Trovik, J., Kalland, K. H., Salvesen, H. B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10334 · Cited by 68
“It is expressed in several tissues, including the uterus, where its role is largely unknown [10, 11].”
Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review)
Li, H., Liu, Y., Wang, Y., Zhao, X., & Qi, X. (2021) · Oncology Reports · doi:10.3892/or.2021.8174 · Cited by 74
“According to this hypoth‐ esis, the higher androgen levels observed in menopausal or obese women, and in patients with PCOS, are associated with an increased risk of developing EOC, whereas progesterone reduces the risk of developing EOC (49,50).”
BackgroundEndometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103276 · Cited by 70
Self-citationOse, J., Poole, E. M., Schöck, H., Lehtinen, M., Arslan, A. A., Zeleniuch‐Jacquotte, A., Visvanathan, K., Helzlsouer, K. J., Buring, J. E., Lee, I.-M. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3322 · Cited by 65
“There is limited in vitro evidence to support a role of androgens in the etiology of endometrioid EOC (34, 48).”
BackgroundCirillo, P. M., Wang, E. T., Cedars, M. I., Chen, L.-M., & Cohn, B. A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30144 · Cited by 62
“Molecular evidence also suggests that androgen synthesis and action are involved in ovarian cancer etiology.(42) Therefore, the increased risk of ovarian cancer among PCOS women who express symptoms of hyperandrogenism(42) is consistent with an androgen-related mechanism.”
BackgroundA sting in the tail: the N-terminal domain of the androgen receptor as a drug target
McEwan, I., & Monaghan, A. E. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.181081 · Cited by 55
Hormones and endometrial carcinogenesis
Kamal, A. M., Tempest, N., Parkes, C., Alnafakh, R., Makrydima, S. F., Adishesh, M., & Hapangama, D. K. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0005 · Cited by 54
Molecular Management of High-Grade Serous Ovarian Carcinoma
Punzón-Jiménez, P., Lago, V., Domingo, S., Simón, C., & Mas, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213777 · Cited by 51
“• (b) Androgen/progestin hypothesis: This dual hypothesis acknowledges high androgen levels (usually linked to polycystic ovarian syndrome (PCOS) or obesity) as an EOC risk factor [142–144] and P4 as a protective factor [132,133].”
BackgroundA Role for Androgens in Epithelial Proliferation and Formation of Glands in the Mouse Uterus
Simitsidellis, I., Gibson, D. A., Cousins, F. L., Esnal-Zufiaurre, A., & Saunders, P. T. K. (2016) · Endocrinology · doi:10.1210/en.2015-2032 · Cited by 49
“Androgen-estrogen cross-talk has been implicated in the initiation and progression of endometrial cancers, with androgens acting in an antagonistic manner to the proliferative effects of estrogens, restricting endometrial carcinogenesis (reviewed in (20)).”
BackgroundSelf-citationOse, J., Fortner, R. T., Rinaldi, S., Schöck, H., Overvad, K., Tjønneland, A. M., Hansen, L., Dossus, L., Fournier, A., Baglietto, L., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29000 · Cited by 49
“Androstenedione is the preferential substrate for aromatase, and higher androstenedione synthesis may lead to an increased synthesis of estrogens.(31) The aromatase inhibitor letrozole, has shown to inhibit the progression ERa positive ovarian cancer in mice.”
BackgroundThe Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers
Rižner, T. L., Thalhammer, T., & Özvegy-Laczka, C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00346 · Cited by 40
“The importance of androgens as etiological factors has been supported also by the expression of the androgen receptor and the presence of androgen-metabolizing enzymes in well and moderately differentiated endometrial cancer (Gibson et al., 2014).”
BackgroundAndrogen signalling in the ovaries and endometrium
Lissaman, A. C., Girling, J. E., Cree, L. M., Campbell, R. E., & Ponnampalam, A. P. (2023) · Molecular Human Reproduction · doi:10.1093/molehr/gaad017 · Cited by 45
“…Massafra et al. , 1999; Salonia et al. , 2008; Rothman et al. , 2011; Skiba et al. , 2019; Atukorala et al. , 2022; Kru¨ger et al. , 2023) and relative receptor expression patterns in the endometrium (Mote et al. , 2000; Mertens et al. , 2001; Hapangama et al. , 2015; Gibson et al. , 2018a, 2014).”
BackgroundLing, K., Jiang, L., Shi, L., Kwong, J., Yang, L., Li, Y., PingYin, Deng, Q., & Liang, Z. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0403-2 · Cited by 42
Androgen action in female reproductive physiology
Walters, K. A., Simanainen, U., & Gibson, D. A. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000246 · Cited by 31
“Because of the potential impact of AR-signalling on cell proliferation, there is emerging evidence to suggest that targeting androgen action may be of potential therapeutic benefit in endocrine-dependent gynaecological malignancies such as endometrial and ovarian cancer [42].”
BackgroundSelf-citationMahadik, N. S., Bhattacharya, D., Padmanabhan, A., Sakhare, K. R., Narayan, K. P., & Banerjee, R. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1755 · Cited by 30
Integration of androgen hormones in endometrial cancer biology
Gjorgoska, M., & Rižner, T. L. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.06.001 · Cited by 30
“Several studies have assessed AR expression in different EC grades and types and compared it with that in endometrial hyperplasia, a precursor lesion of EC and healthy endometrial tissue [27,74,75].”
BackgroundHashmi, A. A., Hussain, Z. F., Qadri, A., Irfan, M., Ramzan, S., Faridi, N., Khan, A., & Edhi, M. M. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3403-9 · Cited by 30
“Androgens also display anti-proliferative effect in normal endometrium and therefore can theoretically play a role similar to progestins [7].”
Ito, K., Miki, Y., Suzuki, T., McNamara, K. M., & Sasano, H. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-15-0470 · Cited by 29
Androgen Receptor Expression in Endometrial Carcinoma
Zadeh, S. L., Duska, L., & Mills, A. M. (2017) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000401 · Cited by 29
“Although androgen is typically thought to have antiproliferative effects in the healthy endometrium, its role in endometrial cancer is still being elucidated, with recent speculation that it could represent a target for therapeutic antagonism in some cases (15,16,21,24).”
BackgroundAndrogen receptor signalling in non-prostatic malignancies: challenges and opportunities
Dotto, G. P., Buckinx, A., Özdemir, B. C., & Simon, C. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00772-w · Cited by 28
“In endometrial cancer, AR loss has also been associated with poor survival in women in postmenopause 100 , even if elevated androgen exposure has been linked to increased cancer risk 101 .”
Choi, J. P., Zheng, Y., Giles, K. A., Handelsman, D. J., & Simanainen, U. (2015) · Biology of Reproduction · doi:10.1095/biolreprod.115.132241 · Cited by 28
“Furthermore, a role of androgens in clinical uterine cancers has been proposed [13].”
BackgroundAKR1C3 Is Associated with Better Survival of Patients with Endometrial Carcinomas
Hojnik, M., Šuster, N. K., Smrkolj, Š., Grazio, S. F., Verdenik, I., & Rižner, T. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124105 · Cited by 26
Emerging biomarkers in ovarian granulosa cell tumors
Mills, A. M., Chinn, Z., Rauh, L. A., Dusenbery, A. C., Whitehair, R. M., Saks, E. J., & Duska, L. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000065 · Cited by 24
Role of dihydrotestosterone (DHT) on TGF-β1 signaling pathway in epithelial ovarian cancer cells
Kohan, K., Gabler, F., Selman, A., Vega, M., & Romero, C. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1998-y · Cited by 24
“Our group and others (Elattar et al. 2012; Gibson et al. 2014) have demonstrated an increase in AR protein in EOC that in turn indicates a potential susceptibility of such tissue to androgen action, as it has been found in other tissues, such as the prostate (Zhou et al.”
BackgroundInfluentialThe Role of Androgen Receptor and microRNA Interactions in Androgen-Dependent Diseases
Bielska, A., Skwarska, A., Kretowski, A. J., & Niemira, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031553 · Cited by 23
Environmental fate and toxicity of androgens: A critical review
Huanyu, T., Jianghong, S., Wei, G., Jiawei, Z., Ge, H. M., & Yunhe, W. (2022) · Environmental Research · doi:10.1016/j.envres.2022.113849 · Cited by 23
Risk of Sex-Specific Cancers in Opposite-Sex and Same-Sex Twins in Denmark and Sweden
Ahrenfeldt, L. J., Skytthe, A., Möller, S., Czene, K., Adami, H., Mucci, L. A., Kaprio, J. A., Petersen, I., Christensen, K., & Lindahl‐Jacobsen, R. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0317 · Cited by 22
“org Cancer Epidemiol Biomarkers Prev; 24(10) October 2015 1623”
BackgroundInfluentialStrategies for developing 3D printed ovarian model for restoring fertility
Nair, R., Kasturi, M., Mathur, V., Seetharam, R. N., & Vasanthan, K. S. (2024) · Clinical and Translational Science · doi:10.1111/cts.13863 · Cited by 22
Figueira, M. I., Cardoso, H. J., Correia, S., Maia, C. J., & Socorro, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.017 · Cited by 22
High serum Androgen and Insulin concentrations increase the tendency of Endometrial Carcinoma
Teng, F., Ma, X., Yu, X., Yan, Y., Zhao, J., Gao, J., Gao, C., Wang, Y., Tian, W., & Xue, F. (2020) · Journal of Cancer · doi:10.7150/jca.46391 · Cited by 18
“A recent study has reported high androgen levels as a risk factor of EC [14].”
BackgroundPavlič, R., Gjorgoska, M., Hafner, E., Sinreih, M., Gajser, K., Poschner, S., Jäger, W. R., & Rižner, T. L. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.743403 · Cited by 18
Androgen Receptor Activation Induces Senescence in Thyroid Cancer Cells
Gupta, A., Carnazza, M. A., Jones, M., Darżynkiewicz, Z., Halicka, D. H., O'Connell, T. J., Zhao, H. L., Dadafarin, S., Shin, E. D., Schwarcz, M., et al. (2023) · Cancers · doi:10.3390/cancers15082198 · Cited by 18
Rižner, T. L., & Gjorgoska, M. (2024) · Essays in Biochemistry · doi:10.1042/ebc20230096 · Cited by 16
Female Reproductive Systems: Hormone Dependence and Receptor Expression
Kuan, K., & Saunders, P. T. K. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_2 · Cited by 15
Self-citationPre-eclampsia during pregnancy and risk of endometrial cancer: a systematic review and meta-analysis
Jordão, H. W. T., Herink, K., Eastwood, K., McVicker, L., Kearns, C., & McMenamin, Ú. C. (2023) · BMC Women s Health · doi:10.1186/s12905-023-02408-x · Cited by 15
“In contrast, circulating levels of androgens in women with preeclampsia are elevated approximately two-to three-fold [17] with emerging evidence suggesting that androgens may be important in driving endometrial cancer development and progression [18].”
BackgroundLeone, A. G., Bonadonna, S., Cassani, C., Barcellini, A., Sirico, M., Tagliaferri, B., Maccarone, S., Dalu, D., Ruggieri, L., Ghelardi, F., et al. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2024-000330 · Cited by 12
“Biological background and clinical data in both the general population and transgender population regarding the possible correlations between sex hormones and melanoma are described in online supplemental appendix 1.”
Koivisto, C. S., Parrish, M., Bonala, S., Ngoi, S. M., Torres, A., Gallagher, J., Sanchez‐Hodge, R., Zeinner, V., Nahhas, G. J., Liu, B., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.07.003 · Cited by 12
“Women with elevated circulating androgens have a 2–3 fold increased risk of developing endometrial cancer and administration of synthetic androgens to mice results in endometrial hyperplasia [2].”
Steroid metabolism and hormonal dynamics in normal and malignant ovaries
Beevors, L., Sundar, S. S., & Foster, P. (2024) · Essays in Biochemistry · doi:10.1042/ebc20240028 · Cited by 11
Jin, C., Hacking, S. M., Chavarria, H., Bhuiya, T. A., & Khutti, S. (2021) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000756 · Cited by 11
Steroids receptors immunohistochemical expression in different sites of endometriosis
Massarotti, C., Badenier, I. M., Paudice, M., Scaglione, G., Remorgida, V., & Vellone, V. G. (2020) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2020.101861 · Cited by 10
Hormone therapy in female-to-male transgender patients: searching for a lifelong balance
Schonäuer, L. M., Dellino, M., Loverro, M., Carriero, C., Capursi, T., Leoni, C., Loverro, G., & Naro, E. D. (2020) · HORMONES · doi:10.1007/s42000-020-00238-2 · Cited by 10
Ledinek, Ž., Sobočan, M., Sisinger, D., Hojnik, M., Büdefeld, T., Potočnik, U., & Knez, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1013463 · Cited by 9
Wang, X. M., Kho, P. F., Ramachandran, D., Bafligil, C., Amant, F. C., Goode, E. L., Scott, R. J., Tomlinson, I. P. M., Evans, D. G., Crosbie, E. J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106590 · Cited by 9
“Despite testosterone having been identified as a therapeutic target in endometrial cancer, it is not clear if testosterone exerts its effects simply as a precursor to estrogen or through other pathways such as androgen receptor signaling (reviewed by Gibson et al.46) Further studies are needed in this area to determin…”
BackgroundMoatamed, N. A., Vahdatshariatpanahi, S., Gjertson, D. W., Sachs, C. R., Kang, Y., Ostrzega, N. L., Huang, J., & Memarzadeh, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291361 · Cited by 9
Androgen signalling and steroid receptor crosstalk in endocrine cancers
Claessens, F., & Tilley, W. D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0274 · Cited by 9
“Extending beyond the breast, Gibson et al. (2014) discuss the AR, not only as a possible factor in the aetiology of endometrial and ovarian cancers, but also its potential use as a therapeutic target for these diseases.”
BackgroundShahin, N. A., Aladily, T. N., Alhaj, N. A., Khader, A. A., Qa'qa’, S. A., Aljaberi, R., Amer, L. G., & Elshebli, S. (2021) · Oman Medical Journal · doi:10.5001/omj.2021.53 · Cited by 8
“Histol Histopathol 2010 Aug;25(8):1009-1016.”
Colina, J. A., Zink, K. E., Eliadis, K., Salehi, R., Gargus, E. S., Wagner, S. R., Moss, K. J., Baligod, S., Li, K., Kirkpatrick, B. J., et al. (2021) · Cancers · doi:10.3390/cancers13081925 · Cited by 6
Androgen-responsive FOXP4 is a target for endometrial carcinoma
Kayahashi, K., Hasan, M., Khatun, A., Kohno, S., Terakawa, J., Horike, S., Toyoda, N., Matsuoka, A., Iizuka, T., Obata, T., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06433-w · Cited by 5
Li, Y., Li, S., Zhang, Y., Shi, S., Qin, S., Wang, C., Du, J., Ma, J., Chen, H., & Cui, H. (2021) · Journal of Cancer · doi:10.7150/jca.51099 · Cited by 5
“Several studies have shown that androgen contributes to the pathogenesis of ovarian cancer [8, 13].”
Hoang, T., Myung, S., & Pham, T. T. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.473 · Cited by 4
“Age, contraceptive use, pregnancy, breastfeeding, and tubal ligation are known to be related to an increased risk of ovarian cancer [2].”
RetractedThe androgen clock is an epigenetic predictor of long-term male hormone exposure
Sugrue, V. J., Prescott, M., Glendining, K. A., Bond, D. M., Horvath, S., Anderson, G. M., Garratt, M., Campbell, R. E., & Hore, T. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2420087121 · Cited by 4
Androgen receptor and intracrine androgen signaling in endometrial carcinomas
(2015) · Receptors & Clinical Investigation · doi:10.14800/rci.853 · Cited by 4
“Many studies have demonstrated the expression of estrogen receptor (ER) in Type I endometrial carcinomas ([4-6]).”
BackgroundShah, F. I., Butt, S. K., Akram, F., Shehzadi, S., Ali, H., & Sabir, S. (2026) · Reproductive Sciences · doi:10.1007/s43032-026-02105-8 · Cited by 2
“However, the common thread of endocrine disruption-especially androgen excess and AR signaling-keeps a plausible mechanistic link open, further warranting research for risk assessment and development of targeted therapies [ 68].”
Recent highlights of research on androgen receptors in women.
Zaręba, K., & Sidorkiewicz, I. (2017) · PubMed Central · doi:10.34763/devperiodmed.20172101.0712 · Cited by 2
“For example, roles of ARs have been studied in such complex processes as reproductive failure (on ovarian, oocytic, and uterine levels), endometrial hyperplasia, and cancer [4-7].”
BackgroundGlandular epithelial AR inactivation enhances PTEN deletion-induced uterine pathology
Choi, J. P., Zheng, Y., Handelsman, D. J., & Simanainen, U. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0039 · Cited by 2
Ling, K., Jiang, L., Shi, L., Kwong, J., Yang, L., Li, Y., PingYin, Deng, Q., & Liang, Z. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0487-3 · Cited by 2
Masoodi, S., Wahid, M. A., Yasin, S. B., Qazi, D., Banday, I., Faizaan, Aiman, A., & Khan, I. Y. (2023) · Indian Journal of Gynecologic Oncology · doi:10.1007/s40944-023-00727-3 · Cited by 1
“Evidence from cell and animal studies suggests that Androgens may have anti-proliferative actions in EC [18].”
BackgroundKim, T. H., Memarzadeh, S., Vahdatshariatpanahi, S., Ostrzega, N. L., Kang, Y., & Moatamed, N. A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322744 · Cited by 1
Current progression of progesterone receptor and androgen receptor in endometrial cancer
Qi, L., Liu, S., Wang, S., Wang, C., & Zhao, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189578 · Cited by 1
The Role of Androgens in Ovarian Follicular Development: From Fertility to Ovarian Cancer
Duda, M., Wartalski, K., Tabarowski, Z., & Gorczyca, G. (2017) · InTech eBooks · doi:10.5772/intechopen.68881 · Cited by 1
“They also stimulate the divisions of the mutated cells [103].”
BackgroundHormone Interactions in Endometrial Cancer
Kamal, A. M., Tempest, N., Maclean, A., Adishesh, M., Bhullar, J., Makrydima, S. F., & Hapangama, D. K. (2019) · Springer eBooks · doi:10.1007/978-3-319-64513-1_6 · Cited by 1
Hiperandrogenizm u kobiet po menopauzie
Kłosowski, P., Świątkowska−Stodulska, R., Berlińska, A., & Sworczak, K. (2017) · Forum Medycyny Rodzinnej
EVALUATION OF SLUG IMMUNOHISTOCHEMICAL EXPRESSION IN ENDOMETRIAL CARCINOMA
Ali Abd El-Fatah Al-Beshkar, M., El-Din Roshdy Matar, E., & Abd El-Naby Omar Awad, N. (2022) · Al-Azhar Medical Journal · doi:10.21608/amj.2022.258349
OATP2B1 as a possible target of hormone dependent cancer treatment
Laczkó-Rigó, R. (2022) · Eötvös Loránd Tudományegyetem · doi:10.15476/elte.2021.150
Sacilotto, L. B., & GUERRAZZI, V. M. (2024) · doi:10.37085/jmm.2024.pre-comasp/
Estrogens and the G protein-coupled estrogen receptor in prostate cancer: angels or demons?
Figueira, M. I. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Proučevanje sinteze androgenov v modelnih celičnih linijah raka endometrija
Šturm, L. (2023) · Repository of the University of Ljubljana (University of Ljubljana)
Jin, X., Werner, H. M. J., & Romano, A. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.106958
Androgen receptor as a therapeutic target in endometrial cancer: a narrative review
Erfani, H., Martynova, A., Matsuzaki, S., Matsuo, K., Roman, L. D., Sood, A. K., Kurnit, K. C., & Westin, S. N. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.104698
Štosir, Ž. L. (2026) · University of Maribor digital library (University of Maribor)
Ledinek, Ž., Sobočan, M., Sisinger, D., Hojnik, M., Büdefeld, T., Potočnik, U., & Knez, J. (2023) · doi:10.3389/fonc.2023.1013463.s001
Metadata
- Authors
- Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K.
- Affiliations
- MRC Centre for Reproductive Health (GB)
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2014-02-28
- Volume
- 21
- Issue
- 4
- Pages
- T203-T218
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2108865532
- Cited by
- 73
- References
- 154
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 6 · 2021: 9 · 2020: 7 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 11 · 2015: 4 · 2014: 2
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- androgen action, endometrial cancer, ovarian cancer, androgen receptor, androgen signaling, androgen production, genetic variants, cancer risk, antiandrogen therapy, tumor progression, endometrium, ovary
- MeSH terms
- Androgen Antagonists, Androgens, Endometrium, Female, Humans, Ovarian Neoplasms, Ovary, Receptors, Androgen, Endometrial Neoplasms, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.